Alzheimer’s

Camelid nanobodies show promise for brain disorders in mice, review says

7. november 2025 Rapporteret af AI Billede genereret af AI Faktatjekket

A Cell Press review published on November 5, 2025, highlights tiny camelid-derived antibodies known as nanobodies as potential tools for treating conditions such as Alzheimer’s disease and schizophrenia. The authors say these proteins can reach brain targets in mice more readily than conventional antibodies and outline key steps before human testing.